{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:49:51Z","timestamp":1764276591353,"version":"3.38.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clinthera.2011.05.048","type":"journal-article","created":{"date-parts":[[2011,6,26]],"date-time":"2011-06-26T09:01:32Z","timestamp":1309078892000},"page":"776-791","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct00641511","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00656357","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00659230","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Teresa","family":"Nunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Francisco","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Vaz-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amilcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2011.05.048_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-200000004-00001","article-title":"Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease","volume":"35","author":"Esler","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ejheart.2008.09.013","article-title":"Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers","volume":"10","author":"Grassi","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.clinthera.2011.05.048_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1113\/expphysiol.2009.047381","article-title":"The 'neuroadrenergic hypothesis' in hypertension: current evidence","volume":"95","author":"Grassi","year":"2010","journal-title":"Exp Physiol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.AACN.0000340718.93742.c4","article-title":"Current concepts of neurohormonal activation in heart failure: mediators and mechanisms","volume":"19","author":"Lee","year":"2008","journal-title":"AACN Adv Crit Care"},{"key":"10.1016\/j.clinthera.2011.05.048_bib5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.HYP.34.4.724","article-title":"Sympathetic activation in the pathogenesis of hypertension and progression of organ damage","volume":"34","author":"Mancia","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2011.05.048_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/clc.4960180804","article-title":"Neuroendocrine changes in heart failure and their clinical relevance","volume":"18","author":"Parmley","year":"1995","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJM199605233342109","article-title":"Beta-adrenergic blockers and survival in heart failure","volume":"334","author":"Pfeffer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.05.048_bib8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.bjp.0701315","article-title":"Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase","volume":"121","author":"Stanley","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2174\/138161280406221011113124","article-title":"Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure","volume":"4","author":"Hegde","year":"1998","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2011.05.048_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00512932","article-title":"Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery","volume":"333","author":"Soares-da-Silva","year":"1986","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1476-5381.1987.tb16828.x","article-title":"A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery","volume":"90","author":"Soares-da-Silva","year":"1987","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib12","series-title":"Cardiovascular Hormone Systems: From Molecular Mechanisms to Novel Therapeutics","first-page":"251","article-title":"Dopamine","author":"Gomes","year":"2008"},{"key":"10.1016\/j.clinthera.2011.05.048_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200201000-00013","article-title":"Role of dopamine receptors in the kidney in the regulation of blood pressure","volume":"11","author":"Jose","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.clinthera.2011.05.048_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0024-3205(64)90031-1","article-title":"Inhibition of dopamine-beta-hydroxylase by disulfiram","volume":"3","author":"Goldstein","year":"1964","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2011.05.048_bib15","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/0006-2952(69)90366-9","article-title":"Dopamine-\u03b2-hydroxylase inhibition by dimethyldithiocarbamate and related compounds","volume":"18","author":"Lippmann","year":"1969","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/231054a0","article-title":"Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta-hydroxylase, affects serotonin and noradrenaline","volume":"231","author":"Hidaka","year":"1971","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2011.05.048_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-3565(25)28447-6","article-title":"In vivo inhibition of dopamine beta-hydroxylase by 1-phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624)","volume":"171","author":"Johnson","year":"1970","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2011.05.048_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2174\/138161280406221011113124","article-title":"Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure","volume":"4","author":"Hegde","year":"1998","journal-title":"Curr Pharma Design"},{"key":"10.1016\/j.clinthera.2011.05.048_bib19","first-page":"050P","article-title":"Kinetic studies on the inhibition of dopamine-\u03b2-hydroxylase by BIA 5-453 [abstract]","volume":"7","author":"Bonif\u00e1cio","year":"2009","journal-title":"pA2 online"},{"key":"10.1016\/j.clinthera.2011.05.048_bib20","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/jm051051f","article-title":"Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase","volume":"49","author":"Beliaev","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2011.05.048_bib21","first-page":"e133","article-title":"Sustained antihypertensive effects of a selective peripheral dopamine-\u03b2-hydroxylase iInhibitor [abstract]","volume":"50","author":"Igreja","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2011.05.048_bib22","first-page":"087P","article-title":"Long-term lowering of blood pressure levels in the SHR by selective peripheral inhibition of dopamine-b-hydroxylase with BIA 5-453 [abstract]","volume":"6","author":"Igreja","year":"2008","journal-title":"pA2 online"},{"key":"10.1016\/j.clinthera.2011.05.048_bib23","first-page":"088P","article-title":"Long-term benefits of the selective peripheral dopamine-\u03b2-hydroxylase inhibitor BIA 5-453 in heart failure [abstract]","volume":"6","author":"Wright","year":"2008","journal-title":"pA2 online"},{"key":"10.1016\/j.clinthera.2011.05.048_bib24","first-page":"39","article-title":"Interspecies differences in pharmacodynamic and disposition of BIA 5-453, a novel dopamine-beta-hydroxylase inhibitor [abstract]","volume":"40","author":"Igreja","year":"2009","journal-title":"Drug Metabol Rev"},{"key":"10.1016\/j.clinthera.2011.05.048_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/157340809787314265","article-title":"Dopamine beta-monooxygenase: mechanism, substrates and inhibitors","volume":"5","author":"Beliaev","year":"2009","journal-title":"Curr Enzyme Inh"},{"key":"10.1016\/j.clinthera.2011.05.048_bib26","article-title":"Single-dose tolerability, pharmacokinetics and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine beta-hydroxylase inhibitor, in healthy subjects","author":"Rocha","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/11586310-000000000-00000","article-title":"Safety, tolerability and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects","volume":"10","author":"Nunes","year":"2010","journal-title":"Drugs R&D"},{"key":"10.1016\/j.clinthera.2011.05.048_bib28","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/carcin\/22.9.1405","article-title":"Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck","volume":"22","author":"Fronhoffs","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clinthera.2011.05.048_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/carcin\/bgi171","article-title":"Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer","volume":"27","author":"Li","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.clinthera.2011.05.048_bib30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000072934","article-title":"N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects","volume":"16","author":"Brocvielle","year":"2003","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"10.1016\/j.clinthera.2011.05.048_bib31","first-page":"22","article-title":"Acetylation genotype and phenotype in patients with systemic lupus erythematosus","volume":"58","author":"Rychlik-Sych","year":"2006","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.clinthera.2011.05.048_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1011503032353","article-title":"On sample size calculation in bioequivalence trials","volume":"28","author":"Chow","year":"2001","journal-title":"J Pharmacokin Pharmacodyn"},{"year":"2000","author":"Gabrielsson","series-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications","key":"10.1016\/j.clinthera.2011.05.048_bib33"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811002840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811002840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:26:33Z","timestamp":1741285593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811002840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0149291811002840"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.05.048","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}